Diabetic neuropathy. Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified
Conditions
Interventions
Intervention 1: Intervention group 1: The study solution consisted of 5 mL sodium chloride hypertonic 5% and 1 mL lidocaine 2% (Pasteur institute of Iran) was injected with a 27-gauge needle near the
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Presence of pain, paresthesia and sympoms of diabetic neuropathy over the past month Ages between 30-60 Complete and sign written consent
Exclusion criteria
Exclusion criteria: Infection, tumor or any skin lesions at the site of intervention Severe foot deformity History of chemotherapy Pregnancy Lumbosacral canal stenosis or discopathy Trauma Rheumatologic and collagen vascular disease(CVD) Spinal cord injury(SCI) Traumatic brain injury(TBI) Cerebrovascular accident(CVA) Other nerve injuries and neuropathies History of coagulopathy disorders History of allergy to the drugs being used in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is an assessment tool for neuropathic pain, called Douleur Neuropathique 4 questionnaire(DN4) score. Timepoint: For each subject, the Douleur Neuropathique 4 questionnaire outcome measure is completed at baseline, first, second and 8th week after treatment. Method of measurement: Douleur Neuropathique 4 questionnaire to assess neuropathic pain. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNina Heidari
Shiraz University of Medical Sciences
Outcome results
None listed